

Curriculum vitae

Omid Mirmosayyeb, MD

Researcher, General practitioner

Institutional Email address:

o.mirmosayyeb@edc.mui.ac.ir

Personal Email address:

omid.mirmosayyeb@gmail.com

Scholar:

<https://scholar.google.com/citations?user=QCjafQIAAAAJ&hl=en&oi=ao>

Researchgate:

<https://www.researchgate.net/profile/Omid-Mirmosayyeb>

Website:

<https://neuromid.com/>

EDUCATION and TRAINING:

۲۰۱۸ Doctorate of Medicine, General Practitioner
Isfahan University of Medical Sciences, Isfahan, Iran,
Completed with GPA: 3.32 (out of 4)

POSITIONS and PROFESSIONAL EXPERIENCE

- Isfahan Neurosciences Research Center

Isfahan University of Medical Sciences, Iran | 2014-present

Position: Head of student research team on Multiple Sclerosis

Responsibilities: I cooperate in designing and conducting research studies, data analysis, and scientific writing.

- Universal Scientific Education and Research Network (UCE group)

Tehran University of Medical Sciences, Iran | 2019-present

Position: Family Physician and researching on Multiple Sclerosis

- Amiralmomenin Hospital

Isfahan University of Medical Sciences | 2019-2020

Position: Family Physician

- Sahebalzaman Hospital

Isfahan University of Medical Sciences | 2019-2020

Position: Family Physician

- Students' Research Center

Isfahan University of Medical Sciences, Iran | 2013-2019

Position: Board member

Responsibilities: Contribution in policy making, strategic planning, and administering of the research center, as well as designing and holding new research training workshops

Awards

2021- Best Oral presentation, 18th International MS congress of Iran, Iran

2020- Best Poster Presentation, 17th International MS congress of Iran, Iran

2019 - Best Poster Presentation, 16th International MS congress of Iran, Iran.

2018- Prominent research student at 27th festival of the best researcher, Ministry of Health and Medical Education, Iran

2018 - Best Poster Presentation, 15th International MS congress of Iran, Iran. 2018 - Best researcher student of Iran, Ministry of health and medical education, Iran.

2018 - Best Student the University, 27th best student festival, Iran.

2017 - Best Oral presentation, 25th International Neurology & Electrophysiology of Iran, Iran.

2014 - Best Researcher Student of Center, Isfahan Neurosciences research center, Iran.

Publications

PubMed publications

1. **Mirmosayyeb O**, Ghaffary EM, Bagherieh S, Barzegar M, Dehghan MS, Shaygannejad V. Post COVID-19 Infection Neuromyelitis Optica Spectrum Disorder (NMOSD): A Case Report-Based Systematic Review. *Multiple Sclerosis and Related Disorders* [Internet]. 2022;103697.
2. Askari M, **Mirmosayyeb O**, Ghaffary EM, Ghoshouni H, Shaygannejad V, Ghajarzadeh M. Incidence of cancer in patients with multiple sclerosis (MS) who were treated with fingolimod: A systematic review and meta-analysis. *Mult Scler Relat Disord*. 2022 Feb 9;59:103680. doi: 10.1016/j.msard.2022.103680. Epub ahead of print. PMID: 35176641.
3. Bagherieh S, Ghoshouni H, Bostan F, Afshari-Safavi A, Badihian S, Barzegar M, Shaygannejad V, **Mirmosayyeb O**. Incidence, prevalence, and characteristics of heart failure among patients with multiple sclerosis: A systematic review and meta-analysis. *Mult Scler Relat Disord*. 2022 Feb 4;59:103665. doi: 10.1016/j.msard.2022.103665. Epub ahead of print. PMID: 35150980.
4. **Mirmosayyeb O**, Barzegar M, Rezaei M, Baharlouie N, Shaygannejad V. Bell's palsy after Sputnik V COVID-19 (Gam-COVID-Vac) vaccination. *Clin Case Rep*. 2022 Feb 23;10(2):e05468. doi: 10.1002/ccr3.5468. PMID: 35228880; PMCID: PMC8867017.
5. Barzegar M, **Mirmosayyeb O**, Rezaei M, Bjørklund G, Nehzat N, Afshari-Safavi A, Shaygannejad V. Prevalence and Risk Factors of Dysphagia in Patients with Multiple Sclerosis. *Dysphagia*. 2022 Feb;37(1):21-27. doi: 10.1007/s00455-021-10245-z. Epub 2021 Feb 12. PMID: 33580368.
6. Ghoshouni H, Bagherieh S, Parvizinia M, Askari M, Sadeghi M, **Mirmosayyeb O**. Unraveling the Mystery of COVID-19 Postvaccination Myocarditis: A Systematic Review of Current Cases.

Kasapcopur O, editor. International Journal of Clinical Practice. 2022;2022:2438913. Available from: <https://doi.org/10.1155/2022/2438913>

7. Sadeghi-Bahmani D, Barzegar M, **Mirmosayyeb O**, Vaheb S, Nehzat N, Shaygannejad V, Brand S. Sociodemographic and Illness-Related Indicators to Predict the Status of Neuromyelitis Optica Spectrum Disorder (NMOSD) Five Years after Disease Onset. *J Clin Med*. 2022 Jan 29;11(3):734. doi: 10.3390/jcm11030734. PMID: 35160189; PMCID: PMC8836947.
8. Sara Bagherieh, Narges Ebraimi, **Omid Mirmosayyeb**, et al. The First Case of Longitudinal Extensive Transverse Myelitis (LETM) Following the First Dose Vaccination with Sinopharm Vaccine. *Authorea*. January 27, 2022.
9. Azadvari M, **Mirmosayyeb O**, Hosseini M, Vaheb S, Razavi SZE. The prevalence of osteoporosis/osteopenia in patients with multiple sclerosis (MS): a systematic review and meta-analysis. *Neurol Sci*. 2022 Jan 17. doi: 10.1007/s10072-022-05871-w. Epub ahead of print. PMID: 35038045.
10. Nouri H, **Mirmosayyeb O**, Badihian S, Shaygannejad V. Radiologically Isolated Syndrome: An Atypical Presentation of Balo's Concentric Sclerosis in a Patient with the Meniere's Disease. *Neurol India*. 2022 Jan-Feb;70(1):439-440. doi: 10.4103/0028-3886.338680. PMID: 35263943.
11. Houshi S, Tavallaei MJ, Barzegar M, Afshari-Safavi A, Vaheb S, **Mirmosayyeb O**, Shaygannejad V. Prevalence of trigeminal neuralgia in multiple sclerosis: A systematic review and meta-analysis. *Mult Scler Relat Disord*. 2022 Jan;57:103472. doi: 10.1016/j.msard.2021.103472. Epub 2021 Dec 29. PMID: 34986455.
12. **Mirmosayyeb O**, Shaygannejad V, Bagherieh S, Hosseinabadi AM, Ghajarzadeh M. Prevalence of multiple sclerosis (MS) in Iran: a systematic review and meta-analysis. *Neurological Sciences*. 2021 Nov 17:1-9.
13. Khoshnood RJ, Zali A, Tafreshinejad A, Ghajarzadeh M, Ebrahimi N, Safari S, **Mirmosayyeb O**. Parkinson's disease and COVID-19: a systematic review and meta-analysis. *Neurological Sciences*. 2021 Nov 17:1-9.
14. Guitynavard F, **Mirmosayyeb O**, Razavi SZ, Hosseini M, Hosseinabadi AM, Ghajarzadeh M, Azadvari M. Percutaneous posterior tibial nerve stimulation (PTNS) for lower urinary tract symptoms (LUTSs) treatment in patients with multiple sclerosis (MS): a systematic review and meta-analysis. *Multiple Sclerosis and Related Disorders*. 2021 Nov 10:103392.
15. Barzegar M, **Mirmosayyeb O**, Ebrahimi N, Bagherieh S, Afshari-Safavi A, Hosseinabadi AM, Shaygannejad V, Asgari N. COVID-19 Susceptibility and Outcomes among Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD): A Systematic Review and Meta-Analysis. *Multiple Sclerosis and Related Disorders*. 2021 Nov 1:103359.
16. Nomura K, Terwilliger P, Alidadiani P, Manian M, Jahanbani-ardakani H, **Mirmosayyeb O**. Self-dual Leonard pairs Expression of OX40 Gene and its Serum Levels in Neuromyelitis Optica Patients a.
17. **Mirmosayyeb O**, Bagherieh S, Shaygannejad V. Acute CNS demyelination in a subject with cerebellar ataxia following the first dose of COVID-19 mRNA vaccine; a case report. *Human Vaccines & Immunotherapeutics*. 2021 Oct 9:1-3.
18. Ghajarzadeh M, Moghadasi AN, **Mirmosayyeb O**, Barzegar M, Sahraian MA. The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): A systematic review and meta-analysis. *Journal of the Neurological Sciences*. 2021 Oct 1;429.

19. Tavallaei MJ, Tavallaei AH, Ebrahimi N, Ghoshouni H, Afshari-Safavi A, Badihian S, Shaygannejad V, **Mirmosayyeb O**. The prevalence of Myocardial Infarction among Multiple Sclerosis Patients: a Systematic Review and Meta-analysis. *Multiple Sclerosis and Related Disorders*. 2021 Sep 30:103292.
20. Imani SZ, Hojati Z, Khalilian S, Dehghanian F, Kheirollahi M, Khorrami M, Shaygannejad V, **Mirmosayyeb O**. Expression and clinical significance of IL7R, NFATc2, and RNF213 in familial and sporadic multiple sclerosis. *Scientific reports*. 2021 Sep 28;11(1):1-0.
21. Zali A, Khoshnood RJ, Motavaf M, Salimi A, Akhlaghdoust M, Safari S, Ghajarzadeh M, **Mirmosayyeb O**. Deep brain stimulation for multiple sclerosis tremor: A systematic review and meta-analysis. *Multiple Sclerosis and Related Disorders*. 2021 Sep 6:103256.
22. Barzegar M, Najdaghi S, Afshari-Safavi A, Nehzat N, **Mirmosayyeb O**, Shaygannejad V. Early predictors of conversion to secondary progressive multiple sclerosis. *Multiple sclerosis and related disorders*. 2021 Sep 1;54:103115.
23. Abbasirad F, Shaygannejad V, Hosseininasab F, **Mirmosayyeb O**, Mahaki B, Moayedi B, Esmail N. Significant immunomodulatory and hepatoprotective impacts of Silymarin in MS patients: A double-blind placebo-controlled clinical trial. *International immunopharmacology*. 2021 Aug 1;97:107715.
24. Nehzat N, **Mirmosayyeb O**, Barzegar M, Vosoughi R, Fazeli E, Shaygannejad V. Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis. *Neurology Research International*. 2021 Jul 15;2021.
25. Barzegar M, **Mirmosayyeb O**, Gajarzadeh M, Afshari-Safavi A, Nehzat N, Vaheb S, Shaygannejad V, Maghzi AH. COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review. *Neurology-Neuroimmunology Neuroinflammation*. 2021 Jul 1;8(4).
26. Barzegar M, Vaheb S, **Mirmosayyeb O**, Afshari-Safavi A, Nehzat N, Shaygannejad V. Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study. *Multiple Sclerosis and Related Disorders*. 2021 Jul 1;52:102947.
27. **Mirmosayyeb O**, Barzegar M, Afshari-Safavi A, Nehzat N, Heidari A, Emami P, Shaygannejad V. Evaluation of Month of Birth in Neuromyelitis Optica Spectrum Disorders (NMSOD) and Multiple Sclerosis (MS). *Multiple Sclerosis International*. 2021 Jun 10;2021.
28. Moghadasi AN, **Mirmosayyeb O**, Barzegar M, Sahraian MA, Ghajarzadeh M. The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis. *Neurological Sciences*. 2021 Jun 7:1-7.
29. Shaygannejad V, **Mirmosayyeb O**, Nehzat N, Ghajarzadeh M. Fear of relapse, social support, and psychological well-being (depression, anxiety, and stress level) of patients with multiple sclerosis (MS) during the COVID-19 pandemic stage. *Neurological Sciences*. 2021 Apr 15:1-4.
30. Khalilian S, Hojati Z, Dehghanian F, Shaygannejad V, Imani SZ, Kheirollahi M, Khorrami M, **Mirmosayyeb O**. Gene expression profiles of YAP1, TAZ, CRB3, and VDR in familial and sporadic multiple sclerosis among an Iranian population. *Scientific reports*. 2021 Apr 8;11(1):1-0.
31. **Mirmosayyeb O**, Ebrahimi N, Shekarian A, Bagherieh S, Afshari-Safavi A, Shaygannejad V, Barzegar M. Prevalence of dysphagia in patients with multiple sclerosis; a systematic review and meta-analysis. *medRxiv*. 2021 Jan 1.
32. **Mirmosayyeb O**, Shaygannejad V, Barzegar M, Nehzat N. Efficacy and safety of rituximab in treating patients with Neuromyelitis optica spectrum disorder (NMOSD): A systematic review

- and meta-analysis. *Autoimmun Rev.* 2020 Dec 16:102727. doi: 10.1016/j.autrev.2020.102727. Epub ahead of print. PMID: 33340771.
33. Shahpouri MM, Barekatin M, Tavakoli M, **Mirmosayyeb O**, Safaei A, Shaygannejad V. Comparison of Cognitive Rehabilitation versus Donepezil Therapy on Memory Performance, Attention, Quality of Life, and Depression among Multiple Sclerosis Patients. *Neurol Res Int.* 2020 Nov 22; 2020:8874424. doi: 10.1155/2020/8874424. PMID: 33299606; PMCID: PMC7704202.
 34. Barzegar M, Allahdadian S, **Mirmosayyeb O**, Azarbajehani R, Badihian S, Nehzat N, Daryanavardi S, Barzegar S, Shaygannejad V. Short report: assessment of coping strategies in patients with neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis. *Psychol Health Med.* 2020 Dec 10:1-11. doi: 10.1080/13548506.2020.1859564. Epub ahead of print. PMID: 33300373.
 35. Barzegar M, Sadeghi Bahmani D, **Mirmosayyeb O**, Azarbajehani R, Afshari-Safavi A, Vaheb S, Nehzat N, Dana A, Shaygannejad V, Motl RW, Brand S. Higher Disease and Pain Severity and Fatigue and Lower Balance Skills Are Associated with Higher Prevalence of Falling among Individuals with the Inflammatory Disease of Neuromyelitis Optica Spectrum Disorder (NMOSD). *J Clin Med.* 2020 Nov 9;9(11):3604. doi: 10.3390/jcm9113604. PMID: 33182291; PMCID: PMC7695277.
 36. **Mirmosayyeb O**, Barzegar M, Nehzat N, Shaygannejad V, Sahraian MA, Ghajarzadeh M. The prevalence of migraine in multiple sclerosis (MS): A systematic review and meta-analysis. *J Clin Neurosci.* 2020 Sep;79:33-38. doi: 10.1016/j.jocn.2020.06.021. Epub 2020 Aug 4. PMID: 33070914.
 37. Ramezani N, Adibi I, **Mirmosayyeb O**, Shaygannejad V. MS Care in Novel Coronavirus 19 Pandemic. *Int J Prev Med.* 2020 Jul 9;11:98. doi: 10.4103/ijpvm.IJPVM_242_20. PMID: 33042495; PMCID: PMC7518361.
 38. **Mirmosayyeb O**, Vaheb S, Barzegar M, Shaygannejad V, Bonavita S, Ghajarzadeh M. Screening neuromyelitis optica patients for COVID-19 infection. *Autoimmun Rev.* 2020 Nov;19(11):102669. doi: 10.1016/j.autrev.2020.102669. Epub 2020 Sep 14. PMID: 32942032; PMCID: PMC7489250.
 39. Cheshmavar M, **Mirmosayyeb O**, Badihian N, Badihian S, Shaygannejad V. Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial. *Acta Neurol Scand.* 2020 Sep 8. doi: 10.1111/ane.13344. Epub ahead of print. PMID: 32897569.
 40. **Mirmosayyeb O**, Shaygannejad V, Ghajarzadeh M. Comparison of Psychological Difficulties in Patients with Migraine and Epilepsy Using PARADISE-24 Questionnaire. *J Multidiscip Healthc.* 2020 Jul 10;13:609-613. doi: 10.2147/JMDH.S260056. PMID: 32764953; PMCID: PMC7368128.
 41. Sadeghpour N, **Mirmosayyeb O**, Bjørklund G, Shaygannejad V. Is Fertility Affected in Women of Childbearing Age with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder? *J Mol Neurosci.* 2020 Nov;70(11):1829-1835. doi: 10.1007/s12031-020-01576-x. Epub 2020 Aug 1. PMID: 32740781.
 42. Barzegar M, **Mirmosayyeb O**, Ghajarzadeh M, Nehzat N, Vaheb S, Shaygannejad V, Vosoughi R. Characteristics of COVID-19 disease in multiple sclerosis patients. *Mult Scler Relat Disord.* 2020 Oct;45:102276. doi: 10.1016/j.msard.2020.102276. Epub 2020 Jun 8. PMID: 32652473; PMCID: PMC7278648.
 43. Ghajarzadeh M, **Mirmosayyeb O**, Barzegar M, Nehzat N, Vaheb S, Shaygannejad V, Maghzi AH. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on

- ocrelizumab during the pandemic. *Mult Scler Relat Disord*. 2020 Aug;43:102222. doi: 10.1016/j.msard.2020.102222. Epub 2020 May 23. PMID: 32464586; PMCID: PMC7245286.
44. Barzegar M, **Mirmosayyeb O**, Nehzat N, Sarrafi R, Khorvash F, Maghzi AH, Shaygannejad V. COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. *Neurol Neuroimmunol Neuroinflamm*. 2020 May 5;7(4):e753. doi: 10.1212/NXI.0000000000000753. PMID: 32371550; PMCID: PMC7217655.
45. **Mirmosayyeb O**, Brand S, Barzegar M, Afshari-Safavi A, Nehzat N, Shaygannejad V, Sadeghi Bahmani D. Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis. *J Clin Med*. 2020 May 2;9(5):1326. doi: 10.3390/jcm9051326. PMID: 32370288; PMCID: PMC7290335.
46. Shaygannejad V, Sadeghi Bahmani D, Soleimani P, **Mirmosayyeb O**, Barzegar M, Amra B, Brand S. Comparison of prevalence rates of restless legs syndrome, self-assessed risks of obstructive sleep apnea, and daytime sleepiness among patients with multiple sclerosis (MS), clinically isolated syndrome (CIS) and Neuromyelitis Optica Spectrum Disorder (NMOSD). *Sleep Med*. 2020 Jun;70:97-105. doi: 10.1016/j.sleep.2019.11.1266. Epub 2019 Dec 17. PMID: 32276200.
47. Barkhordari S, **Mirmosayyeb O**, Mansourian M, Hosseininassab F, Ramezani S, Barzegar M, Amin MM, Poursafa P, Esmail N, Kelishadi R. Omega 3 Supplementation Can Regulate Inflammatory States in Gas Station Workers: A Double-Blind Placebo-Controlled Clinical Trial. *J Interferon Cytokine Res*. 2020 May;40(5):262-267. doi: 10.1089/jir.2019.0220. Epub 2020 Mar 13. PMID: 32176565.
48. Mahtab Fattahi, Nahid Rezaei, Fattah Sotoudehnejad Nematalahi, Vahid Shaygannejad, Salomeh Fouladi, Leila Karimi, Farshid Fathi, Leila Dehghani, **Omid Mirmosayyeb**, Nahid Eskandari. MicroRNA-29b variants and MxA expression change during interferon beta therapy in patients with relapsing-remitting multiple sclerosis. *Multiple sclerosis and related disorders*. 2019 October 1
49. Mahdi Barzegar, D Sadeghi Bahmani, Nasim Nehzat, Marjan Kiani, Niloofar Hashemi, **Omid Mirmosayyeb**, Serge Brand, Vahid Shaygannejad. Comparison of sleep complaints and quality of life between patients with neuromyelitis optica spectrum disorder (NMOSD) and healthy controls. *Multiple sclerosis and related disorders*. 2019 July 1
50. Maryam Shariati, Vahid Shaygannejad, Faezeh Abbasirad, Fahimeh Hosseininassab, Mohammad Kazemi, **Omid Mirmosayyeb**, Nafiseh Esmail. Silymarin Restores Regulatory T Cells (Tregs) Function in Multiple Sclerosis (MS) Patients In Vitro. *Inflammation*. 2019 February 26
51. Fereshteh Navabi, Vahid Shaygannejad, Faezeh Abbasirad, Elaheh Vaez, Fahimeh Hosseininassab, Mohammad Kazemi, **Omid Mirmosayyeb**, Fereshteh Alsahebhosoul, Nafiseh Esmail. Immunoregulatory Effects of Silymarin on Proliferation and Activation of Th1 Cells Isolated from Newly Diagnosed and IFN- β 1b-Treated MS Patients. *Inflammation*. 2019 February 15
52. Shaygannejad V, Fayyazi E, Badihian S, **Mirmosayyeb O**, Manouchehri N, Ashtari F, Asgari N. Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study. *Journal of Neurology*. 2019 January 11.
53. Badihian S, Shaygannejad V, Soleimani P, **Mirmosayyeb O**, Samee Z, Manouchehri N, Esmail N. Decreased serum levels of interleukin-35 among multiple sclerosis patients may be related to disease progression. *Journal of Biological Regulators and Homeostatic Agents*. 2018 September/October.

54. Behrouz Robot-Jazi, Mina Hosseini, Vahid Shaygannejad, Shahriar Nafissi, Abbas Rezaei, Marjan Mansourain, **Omid Mirmosayyeb**, Nafiseh Esmaeil. High Frequency of Tc22 and Th22 Cells in Myasthenia Gravis Patients and Their Significant Reduction after Thymectomy. Neuroimmunomodulation. 2018 August 2
55. Vahid Shaygannejad, Mohammad Bagher Maljaei, Sahar Saraf Bank, **Omid Mirmosayyeb**, Mohammad Reza Maracy, Gholamreza Askari. Association between sun exposure, Vitamin D intake, serum Vitamin D level, and immunoglobulin G level in patients with neuromyelitis optica spectrum disorder. International journal of preventive medicine. 2018 August 14
56. Badihian S, Manouchehri N, **Mirmosayyeb O**, Ashtari F, Shaygannejad V. Neuromyelitis optica spectrum disorder and menstruation. Revue Neurologique. 2018 July 23.
57. **Omid Mirmosayyeb**, Emad Fayyazi, Vahid Shaygannejad, Nafiseh Esmaeil. Lower extremity deep venous thrombosis in a multiple sclerosis patient on dimethyl fumarate. Multiple sclerosis and related disorders. 2018 July 21
58. Vahid Shaygannejad, Emad Fayyazi, **Omid Mirmosayyeb**, Nafiseh Toghianifar. Immune Thrombocytopenia (ITP) in a Patient with Relapsing-Remitting Multiple Sclerosis (RRMS) Associated with b-Interferon-1 α Treatment. Indian Journal of Pharmaceutical Education and Research. 2018 July 1
59. Fereshte Ashtari, Nafiseh Esmaeil, Marjan Mansourian, Parinaz Poursafa, **Omid Mirmosayyeb**, Mahdi Barzegar, Hajar Pourghesari. An 8-year study of people with multiple sclerosis in Isfahan, Iran: Association between environmental air pollutants and severity of disease. Journal of neuroimmunology. 2018 June 15
60. Barzegar M, Badihian S, **Mirmosayyeb O**, Ashtari F, Jamadi M, Emami S, Jahani L, Safavi A, Shaygannejad V. Comparative study of quality of life, anxiety, depression, and fatigue among patients with neuromyelitis optica spectrum disorder and multiple sclerosis: The first report from Iran. Multiple Sclerosis and Related Disorders. 2018 April 14.
61. Mehri Salari, Mahdi Barzegar, Masoud Etemadifar, **Omid Mirmosayyeb**. Serum leptin levels in Iranian patients with Parkinson's disease. Iranian journal of neurology. 2018 April 4
62. Mehri Salari, Emad Fayyazi, **Omid Mirmosayyeb**. Magnetic resonance imaging findings in diagnosis and prognosis of Wilson disease. Journal of research in medical sciences. 2018 March 27
63. Azadeh Seyedjoodaki, Fereshteh Alsahebfoosoul, Nahid Eskandari, Vahid Shaygannejad, Mansour Salehi, Mohammad Kazemi, Mostafa Manian, **Omid Mirmosayyeb**, Mohammad Taghi Kardi. OX40 Gene and Serum Protein Expression Profiles in Patients with Parkinson's Disease. Cell Journal (Yakhteh). 2018 March 18
64. Mina Hosseini, Behrouz Robot-Jazi, Vahid Shaygannejad, Shahriar Nafissi, **Omid Mirmosayyeb**, Abbas Rezaei, Marjan Mansourian, Nafiseh Esmaeil. Increased Proportion of Tc17 and Th17 Cells and Their Significant Reduction after Thymectomy May Be Related to Disease Progression in Myasthenia Gravis. Neuroimmunomodulation. 2018 February 8
65. **Mirmosayyeb O**, Badihian S, Manouchehri N, Kahid Basiri A, Barzegar M, Esmaeil N, Fayyazi E, Shaygannejad V. The interplay of multiple sclerosis and menstrual cycle: Which one affects the other one?. Multiple Sclerosis and Related Disorders. 2018 February 2
66. Mehri Salari, **Omid Mirmosayyeb**, Masoud Etemadifar, Vahid Shaygannejad, Fariborz Khorvash, Mohammad Reza Najafi, Fereshteh Ashtari, Ahmad Chitsaz. Demographic

features and clinical characteristics of patients with Parkinson's disease in Isfahan, Iran. Iranian journal of neurology. 2018 January 5

67. Manouchehri N, **Mirmosayyeb O**, Badihian S, Shaygannejad V. Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod. Multiple Sclerosis and Related Disorders. 2018 Jan.
68. Azadeh Seyedjoodak, Fereshteh Alsahebhosoul, Nahid Eskandari, Vahid Shaygannejadi, Mansour Salehi, Mohammad Kazemi, Mohammad Taghi Kardi, **Omid Mirmosayyeb**. Study of Expression Rate of OX40 Gene in Peripheral Blood in Patients with Parkinson's Disease. Iranian Journal of Allergy, Asthma & Immunology. 2018 January 2

Journal publications

1. Farid Nasr Esfahani, Navid Manouchehri, Nasim Nehzat, **Omid Mirmosayyeb**, Mahdi Barzegar, Vahid Shaygannejad. Caspian Journal of Neurological Sciences. Comparison of Bladder Dysfunction and Urinary Symptoms Between Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. 2019 August 10
2. Navid Manouchheri, **Omid Mirmosayyeb**, Majid Ghasemi, Shervin Badihian, Vahid Shaygannejad, Mahdi Barzegar. Post-treatment Guillain-Barre Syndrome in a Patient with Brucellosis; A Case Report. Internal Medicine and Medical Investigation Journal. 2019 May 10
3. Navid Manouchehri, Nasim Nehzat, **Omid Mirmosayyeb**, Vahid Shaygannejad, Mahdi Barzegar. Tumefactive Brain Lesions in Patients with Neuromyelitis Optica Spectrum Disorder. Caspian Journal of Neurological Sciences. 2019 May 10
4. Mahboubeh Jazini, Rasoul Roghanian, **Omid Mirmosayyeb**, Vahid Shaygannejad, Esfahani Sayyed Hamid Zarkesh. Assessment the Possible Association Between Neuromyelitis Optica and Cytomegalovirus as a Provocative Factor. CASPIAN JOURNAL OF NEUROLOGICAL SCIENCES. 2019 January 1
5. **Mirmosayyeb O**, Manouchehri N, Toghiani N, Dehghani A, Golabchi K, Dehghani L, Badihian S, Fayyazi E, Shaygannejad V. Investigation of the Thickness of the Retinal Nerve Fiber in Multiple Sclerosis Recurring-Recovery: A longitudinal Study. Research on Medicine. 2018 July 14.
6. M Jamalian, V Shaygannejad, S Kheiri, M Sedehi, **O Mirmosayyeb**. Journal of Isfahan Medical School. Comparison effect of prescription drugs on the occurrence and the number of attacks in patients with multiple sclerosis. 2018 January 1
7. Fayyazi E, Shaygannejad V, Maljaei MB, **Mirmosayyeb O**, Badihian S, Moosavian SP. Association between sunlight exposure and vitamin D intake with multiple sclerosis disability and progression. Caspian Journal of Neurological Sciences. 2018 July 1.
8. Effect of cerebrolysin in patients with ischemic stroke: A double-blind randomized control study. Seyed Ali Mousavi, Azam Moradi, **Omid Mirmosayyeb**, Mansour Salehi, Fariborz Khorvash. American Journal of Experimental and Clinical Research. 2017 October 9
9. F Khorvash, M Ghasemi, M Naderi, **O Mirmosayyeb**. A comparative study of the prescription of memantine and piracetam in poststroke aphasia. Journal of Isfahan Medical School. 2015
10. Masoud Etemadifar, **Omid Mirmosayyeb**, Nahid Eskandari. Effects of thymectomy on multiple sclerosis with myasthenia gravis. American Journal of Experimental and Clinical Research. 2014 September 20

Local publications (BOOKS, Journal PUBLICATIONS)

1. **Mirmosayyeb.O**, Chitsaz.A, Vaheb.S, Ghoshouni,H, Etesami.Z(2021).Successful live with Parkinson,Vajhiran publication
2. **Mirmosayyeb.O**,Shirani.K, Esmaeil.N, Nehzat.N, Tavalalaie.MJ, Moases.E , Khalilian.P, Sadeghian.K, Saadat.M, Radandish.M, Ebrahimi.N, Vaheb.S, Yahyazade.S. (2020).COVID-19. Vajhiran publication
3. **Mirmosayyeb.O**, Shayannejad.V, Nehzat.N, Fayyazi.E, Lotfi.F, Vaheb.S, Bathaie.R.(2020) Successful live with Multiple sclerosis.Vajhiran publication
4. **Mirmosayyeb.O**, Shaygannejad.V, Nehzat.N, Barzegar.M, Afshar.F, Molavi.Z, Mohamadi.S. (2019).Successful live with NMOSD.Vajhiran publication
5. **Mirmosayyeb.O**, Shaygannejad.V, Eskandari.N, Esmaeil.N, Barzegar.M, Dehbashi.M, Dehghani.L, Sadrameli.M, Fayyazi.M, Maljaie.MB, Nazari.F.(2018),Multiple sclerosis for physicians.Vajhiran publication
6. **Mirmosayyeb.O**, Eskandari.O, Fayyazi.E, Pourjafari.MS, Bemanalizade.M, Mirzajani.H. (2014), Medical immunology,Publications of Isfahan University of Medical Sciences.
7. What is NMOSD. Golbang Journal, 2018 October
8. RTX as MS treatment. Golbang Journal, 2017 October
9. SMART course (School of Mentor-Assisted Research Training). Golbang Journal. 2016 October

Presentations

Oral presentations

- 2021: Shoenfeld Fridays' Mosaic of Autoimmunity weekly e-Meeting – on this FRIDAY – JULY 09, 2021
- 2021: Zabudowicz Center for Autoimmune Diseases, Sheba Medical Center.

- 2021: 3rd Polythematic Panhellenic Congress of Autoimmune Diseases, Rheumatology and Clinical Immunology
- 2021: 2nd international sports nutrition congress of Iran and 6th annual research congress of semnan university of medical sciences
- 2018-2019: Invited Speaker in 26th and 25th international neurology & electrophysiology of Iran, Iran, Tehran.
- 2018: Invited Speaker in 15th international Multiple Sclerosis of Iran, Iran, Tehran.

Poster presentations

- 2018-2: Salt Intake and Disability in Neuromyelitis Optica Spectrum Disorder. Mohammad Bagher Maljaei, Vahid Shaygannejad, Gholamreza Askari, Mohammad Reza Maracy, **Omid Mirmosayyeb**. Actrims Forum 2019. Texas, USA
- 2018-4: The interplay of multiple sclerosis and menstrual cycle: which one affects the other one?. Omid Mimosayyeb, Shervin Badihian, Navid Manouchehri, Vahid Shaygannejad. American Academy of Neurology annual meeting. Los Angeles, USA
- 2018-4: Neuromyelitis Optica spectrum disorder and menstruation. Shervin Badihian, Navid Manouchehri, **Omid Mirmosayyeb**, Vahid Shaygannejad. American Academy of Neurology annual meeting. Los Angeles, USA
- 2017-10: Decreased serum levels of interleukin-35 among patients with relapsing remitting multiple sclerosis. Shervin Badihian, **Omid Mirmosayyeb**, Navid Manouchehri, Nafiseh Esmaeili, Zahra Samee, Vahid Shaygannejad. 7th Joint Ectrims-Actrims meeting, Paris, France
- 2014-2018: Poster presentation in 11th, 12th, 13th, 14th, 15th, International MS congresses, Iran.

Teaching experiences

- Scientific Writing Workshop; 8 hours on journal submission, principals of scientific writing, and writing case report, case series, and letters (2017-8; 2017-9; 2017-10)
- Presentation Skills Workshop; 4 hours on principals of oral and poster presentation in conferences (2016-8)
- Scientific Poster Designing Workshop; 10 hours on principals of a scientific poster (2017-8)
- Medline Workshop; 64 hours on how to search in scientific databases (2018-11; 2017-10; 2017-5; 2016-4; 2016-2; 2015-12; 2015-5; 2014-3; 2014-2)

- Research Methodology Workshop; 38 hours on principals of research methodology (2018-6; 2017-11; 2016-10; 2015-6; 2014-11; 2013-10)

Manuscript reviewing experiences

Some manuscripts of below journals:

- Neuroimage
- Neuropharmacology
- Neurology Research International
- Expert Review of Pharmacoeconomics & Outcomes Research
- Current Medical Research & Opinion
- Cell Journal (Yakhteh)
- Journal of Research in medical sciences
- The International Journal of Neuroscience
- Journal of the neurological sciences
- Children (MDPI)
- International Journal of General Medicine
- Journal of Urology and Renal Diseases
- Personalized Medicine
- Neurology and Therapy
- Cureus
- Phytomedicine
- Scientific Reports
- Advances in Ophthalmology Practice and Research
- Frontiers in Neurology: topic Editor on the Editorial Board of Multiple Sclerosis and Neuroimmunology (special section of Frontiers in Neurology)
- Frontiers in Medicine
- Expert Review of Pharmacoeconomics & Outcomes Research
- Frontiers in Genetics